AstraZeneca PLC
Pharmaceuticals and BiotechnologyFounded 1999- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
AstraZeneca PLC
Company History
Founded 1999 in Cambridge, England
Last reviewed: 2025-07-15 · By Swet Parvadiya
AstraZeneca generated $58.739 billion in Total Revenue in fiscal year 2025, making it the second-largest oncology-focused pharmaceutical company in the world by revenue and the fastest-growing major pharma company among its global top-ten peers, with an 8% constant-exchange-rate increase over 2024 and a compound annual growth rate of approximately 15% since 2020. This performance is driven by 16 blockbuster medicines, including Tagrisso in lung cancer, Farxiga in cardiovascular and metabolic disease, and Ultomiris in rare blood disorders, supported by a pipeline of 186 projects with 19 new molecular entities in late-stage development. Under CEO Pascal Soriot, the company has transformed from a patent-cliff-threatened entity with declining revenue into a science-led growth machine with a sixfold share price appreciation since 2012, and it now targets $80 billion in revenue by 2030 through the launch of at least 20 new medicines. The company employs 89,900 people, operates in more than 125 countries, and maintains a harmonised listing on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. AstraZeneca's reported operating profit reached $13.743 billion in 2025, with core operating profit of $18.4 billion and a core operating margin of 31.3%. The company's net income of $10.233 billion supported a progressive dividend of $3.20 per share, the 23rd consecutive year of dividend payments since the 1999 merger. With 100+ active Phase III trials, a $50 billion U.S. manufacturing commitment, and a $15 billion China investment plan, AstraZeneca is positioned as one of the most dynamic companies in global healthcare. The company's R&D investment of $14.2 billion represents 24% of Total Revenue, funding a pipeline of 186 projects with 19 late-stage new molecular entities. The $50 billion U.S. manufacturing commitment and $15 billion China investment plan demonstrate long-term strategic vision, while the 23 consecutive years of dividend payments reflect financial discipline. AstraZeneca's competitive position is strengthened by its integrated oncology ecosystem, rare disease complement platform, and emerging presence in weight management and cell therapy. The company's geographic diversification, with 25% of revenue from Emerging Markets, provides insulation from single-market policy shocks. The 2025 results, with 8% constant-exchange-rate growth, 16 positive Phase III readouts, and 43 major market approvals, confirm that the innovation engine is firing on all cylinders.
Astra AB grew from a local Swedish apothecary cooperative into one of Europe's most respected pharmaceutical companies, with particular strength in gastrointestinal medicine through Prilosec, anesthesia through Xylocaine, and cardiovascular care through Aptin. The company's research culture, centered in Södertälje, produced consistent innovation until the 1990s, when global competition and the need for scale drove the board to pursue a merger with Zeneca. Astra's peak as an independent company came in the late 1980s and early 1990s, when Prilosec became the world's best-selling drug, generating billions in annual revenue and establishing Astra as a legitimate global player. However, the company's reliance on a single blockbuster and its limited geographic reach outside Scandinavia and Europe made it vulnerable to larger competitors, ultimately leading to the 1999 merger that created AstraZeneca. The 400 founding doctors and apothecaries established a tradition of scientific rigor that persisted for decades, creating a research environment that produced breakthrough medicines but also a corporate culture that was slow to embrace the commercial imperatives of global pharmaceutical marketing.
Zeneca emerged as a standalone pharmaceutical company with a market capitalization of approximately $9 billion, focusing on oncology, cardiovascular, and respiratory therapies. The company's management, led by Sir David Barnes and later Tom McKillop, grew Zeneca rapidly through the 1990s, divesting non-core specialties businesses and positioning the company as an attractive merger partner for Astra. The 1998 decision to pursue a merger of equals with Astra created one of the world's largest pharmaceutical companies. Zeneca's oncology franchise, particularly Zoladex for prostate cancer, provided immediate revenue scale, while its cardiovascular portfolio including Zestril offered complementary primary care products. The company's British management culture, focused on financial discipline and shareholder returns, contrasted with Astra's more research-oriented Swedish approach, a cultural tension that would persist for years after the merger. The demerger from ICI was driven by shareholder pressure to unlock value, as pharmaceutical operations traded at higher multiples than commodity chemicals, and Zeneca's subsequent growth validated this strategic thesis.
400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies. The cooperative structure emphasized local production and scientific research, with initial products including antiseptics and anesthetics. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales. The demerger creates the first major UK-focused pharmaceutical company since Glaxo's formation. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
The $67 billion merger of equals creates AstraZeneca PLC on April 6, 1999, with Zeneca shareholders receiving 53.5% and Astra shareholders 46.5%, producing a combined company with $14 billion in pro forma sales and headquarters in London. The merger requires FTC divestiture of levobupivacaine rights to preserve competition. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca launches Nexium (esomeprazole), the follow-on to Prilosec, which would become the company's flagship gastrointestinal product and generate peak annual sales exceeding $5 billion before patent expiration. The launch establishes AstraZeneca's ability to extend franchise value through follow-on molecules. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires Cambridge Antibody Technology for $892 million, gaining antibody discovery capabilities that would later support the development of Imfinzi and other biologics. The acquisition signals AstraZeneca's strategic pivot toward large-molecule therapeutics. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment. Soriot immediately halts share buybacks and commits to increasing R&D spending. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca's board rejects a $119 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential. The decision preserves independence but triggers short-term shareholder criticism. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
The FDA approves Tagrisso (osimertinib) for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market. Tagrisso generates $423 million in its first year and establishes the foundation for AstraZeneca's oncology resurgence. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing unprecedented survival benefits. The approval creates a new treatment category and establishes AstraZeneca in immuno-oncology. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak. The vaccine generates $3.9 billion in 2021 revenue before demand declines. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston. The acquisition adds $6 billion in immediate annual revenue. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires CinCor Pharma for $1.1 billion to access baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension, expanding the cardiovascular pipeline beyond SGLT2 inhibitors. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% actual increase and 21% constant exchange rate increase, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% constant exchange rate increase, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies. This milestone shaped AstraZeneca's strategic trajectory and contributed to the company's evolution into a leading global biopharmaceutical enterprise.
AstraZeneca acquired Alexion to enter the rare disease market with a proven complement-biology platform, gaining Soliris and Ultomiris as immediate blockbuster revenue drivers and establishing a dedicated rare disease unit headquartered in Boston. The acquisition provided scientific expertise in immunology that AstraZeneca lacked internally, along with specialized commercial infrastructure for ultra-rare disease diagnosis and patient identification. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired MedImmune to gain biologics manufacturing capabilities, antibody technology platforms, and the Synagis respiratory syncytial virus franchise. The deal represented AstraZeneca's recognition that the future of pharmaceutical innovation lay in large-molecule biologics rather than small-molecule chemistry alone. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired Cambridge Antibody Technology for $892 million to secure antibody discovery and humanization technologies that would accelerate the company's transition from small molecules to biologics. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired the respiratory portfolio of Spanish pharmaceutical company Almirall, including Eklira and rights to a pipeline of COPD and asthma candidates, to strengthen its position in the respiratory market ahead of Symbicort's patent expiration. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired Fusion Pharmaceuticals for $2 billion in cash to access radiopharmaceutical and antibody-drug conjugate technologies, particularly the targeted alpha therapies platform that delivers potent radioisotopes directly to cancer cells. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired Gracell Biotechnologies for $1.2 billion to access autologous cell therapy manufacturing capabilities and the FasTCAR platform, which reduces CAR-T production time from weeks to days. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired CinCor Pharma for $1.1 billion to access baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension and primary aldosteronism, expanding the cardiovascular pipeline beyond SGLT2 inhibitors. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
AstraZeneca acquired Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology that delivers CAR-T genetic modifications directly within the patient's body, eliminating the need for ex vivo manufacturing. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.